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Interrogating molecular data for medulloblastoma risk 
stratification
Medulloblastoma is the most common malignant 
paediatric brain tumour, with an incidence between 
2·34 and 5·96 per million population.1 Early 
studies on medulloblastoma biology were largely 
inconclusive because of its molecular heterogeneity 
and the small size of the cohorts analysed. By contrast, 
more recent studies, based on a large number of 
internationally collected cases, have produced a deeper 
understanding of the molecular events that characterise 
medulloblastoma. Indeed, on the basis of gene 
expression, genetic aberrations, and DNA methylation, 
medulloblastoma is now classified into several 
molecular subgroups.2–5 The 2016 WHO Classification 
of Tumors of the Central Nervous System6 combines 
molecular and histological features for an innovative 
integrated diagnosis, thus allowing stratification of 
patients into four prognostic risk categories: favourable, 
standard, high, and very high risk.3
The standard-risk medulloblastoma category is 
heterogeneous, comprising 50–60% of patients with 
medulloblastoma and encompassing SHH-activated 
TP53wild-type and groups 3 and 4, in the absence of high-
risk features (ie, MYC amplification, anaplastic histology, 
or metastasis at diagnosis). The therapeutic regimen for 
standard-risk medulloblastoma includes radiotherapy 
followed by chemotherapy, with a 5-year progression-
free survival of 75–85%. However, surviving patients 
have a heavy burden of long-term severe endocrine 
and neurological sequelae.7 Therefore, there is urgent 
need for identification of patients with good prognosis 
who could benefit from therapy de-escalation, which 
maintains curative potential while minimising adverse 
effects.
To this aim, the pan-European SIOP PNET 5 clinical 
trial (NCT02066220) is testing a reduced treatment 
scheme for the favourable-risk category, which consists 
of patients with WNT-positive medulloblastoma 
younger than 16 years. Unfortunately, patients meeting 
these inclusion criteria account for only roughly 8% of 
all medulloblastomas.
In The Lancet Oncology, Tobias Goschzik and colleagues8 
did a whole chromosomal aberration analysis of 
standard-risk medulloblastoma and investi gated the 
association between molecular features and progression-
free survival, taking advantage of available samples from 
the completed pan-European HIT-SIOP PNET 4 trial,9 
with the intent of improving prog nosis prediction. They 
found a new prognostic genetic biomarker signature—
defined as at least two events among chromosome 7 
gain, chromosome 8 loss, and chromosome 11 loss—
associated with good prognosis (5-year progression-
free survival of 100% in the HIT-SIOP PNET 4 cohort) 
in patients with non-WNT/non-SHH standard-risk 
medulloblastoma.
The identified risk stratification scheme was a more 
solid model with respect to previous ones, allowing 
reallocation of a subset of patients with standard-
risk medulloblastoma into a favourable-risk group. 
Crucially, the proposed risk stratification applies to 
51% of standard-risk medulloblastomas, and thus 
to 25–30% of all patients with medulloblastoma. 
Consequently, these findings increase the number 
of patients who could be enrolled for therapy de-
escalation in future clinical trials.
As mentioned, methylation and gene expression 
analyses have produced an immense amount of 
important data that provided deep insight into the 
molecular events that underlie pathogenesis and 
laid the foun dation for the development of targeted 
therapies.2–5 Data from genomic analyses are in clinical 
use for patient risk stratification, with molecular 
genomic biomarkers (ie, TP53 mutational status 
and CMYC or NMYC amplification) being an integral 
element of the latest WHO classification.6 Goschzik and 
colleagues generated a whole chromosomal aberration 
signature that can group patients who share the same 
prognosis, even though they are classified in different 
molecular subgroups.8 Indeed, the identified whole 
chromosomal aberration signature-positive class 
included patients with MBGrp4-LowRisk3 and Group3 and 
Group4 subgroups VI and VII.4 Important points that 
strengthen the reported results8 are clinical evidence of 
the proven utility of molecular data investigation, use 
of a strictly defined and well-characterised population 
(HIT-SIOP PNET 4 trial cohort) for generation of the 
data, and validation of the proposed model in an 
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independent patient cohort with matched demographic 
characteristics.
Another class of molecular biomarkers that should 
be considered for implementation of stratification 
risk models in medulloblastoma is non-coding RNAs. 
microRNAs and long non-coding RNAs have been 
shown to be important regulators of medulloblastoma 
biology, and could represent valuable biomarkers for risk 
stratification and targeted therapy.10
In conclusion, this study8 provides a tool for immediate 
clinical application. Although these results require 
validation in a controlled multicentre study, they set the 
foundation that is needed to improve genomic patient 
characterisation for more accurate risk stratification in 
routine clinical settings.
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